NSE · LUPIN · Pharmaceuticals
Lupin Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹5,235 Cr with net profit ₹2,164 Cr — a 41.33% net margin, versus 18.36% the period before.
Shareholding
As of 2026-06-30
- Promoter46.85%
- Public6.08%
- FII22.42%
- DII24.65%
3,00,283 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.38× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #4 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,83,898 Cr | 38.93 | 5.79 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,060 Cr | 214.53 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,319 Cr | 20.68 | 4.14 | 18.59% | 18.86% |
| Lupin Limited(this company) | ₹1,11,601 Cr | 19.62 | 4.97 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,949 Cr | 53.09 | 6.56 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,554 Cr | 88.29 | 18.22 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,545 Cr | 100.47 | 2.44 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,748 Cr | 295.07 | 5.05 | 16.66% | 15.65% |
| Biocon Ltd. | ₹68,726 Cr | 536.71 | 2.02 | 1.14% | 2.3% |
AI analysis
AI-generated · google/gemini-2.5-flashLupin Limited has a market capitalization of Rs 111711 Cr. The company's revenue for the last fiscal year was Rs 22909.51 Cr. Its Price-to-Earnings (PE) ratio stands at 28.2, with an Earnings Per Share (EPS) of 72.41.
Positives
- +The debt-to-equity ratio is low at 0.27.
- +The Return on Capital Employed (ROCE) is 24.88%, indicating efficient use of capital.
- +Promoter shareholding is largely stable, with 46.86% in Mar 2026.
- +The company has no promoter shares pledged.
Negatives
- −Promoter holding decreased from 47.01% in Mar 2018 to 46.86% in Mar 2026.
- −FII holding decreased from 25.39% in Mar 2018 to 21.71% in Mar 2026.
Financial Performance
Lupin Limited reported an annual revenue of Rs 29038.95 Cr for the period ending Mar 2026, with a net profit of Rs 5332.84 Cr and EBITDA of Rs 7864.95 Cr. For the Dec 2025 quarter, revenue was Rs 7167.52 Cr, net profit Rs 1175.55 Cr, and EBITDA Rs 2063.59 Cr. The latest quarterly revenue for Mar 2026 was Rs 7474.66 Cr, with a net profit of Rs 1460.34 Cr and EBITDA of Rs 2179.5 Cr.
Profitability & Returns
The company has a Return on Equity (ROE) of 21% and a Return on Capital Employed (ROCE) of 24.88%. The Earnings Per Share (EPS) for the Mar 2026 annual period was 116.44. The Price-to-Earnings (PE) ratio for the company is 28.2.
Balance Sheet
Lupin Limited maintains a debt-to-equity ratio of 0.27, indicating a relatively low reliance on debt financing. The book value per share is Rs 376.77.
Ownership & Pledges
Public shareholding stands at 6.11%. The number of shareholders as of Mar 2026 is 290411. There are no promoter shares pledged.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.